A phase 1b study of abemaciclib, an inhibitor of CDK4 and CDK6, in combination with endocrine and HER2-targeted therapies for patients with metastatic breast cancer
Autor: | Paul Conkling, B.N. Rexer, Sara M. Tolaney, William Jeffery Edenfield, Shannon Puhalla, Muralidhar Beeram, T.M. Costigan, Teresa Helsten, H. A. Burris, J.T. Beck, Matthew P. Goetz, Shubham Pant, Alison Conlin, C.H. Becerra, Kevin Kalinsky, Edward M. Chan, C. Dees, Maura N. Dickler, S.R.P. Kambhampati, Donald A. Richards |
---|---|
Rok vydání: | 2016 |
Předmět: |
0301 basic medicine
Oncology medicine.medical_specialty biology business.industry Hematology medicine.disease Metastatic breast cancer 03 medical and health sciences chemistry.chemical_compound 030104 developmental biology 0302 clinical medicine Breast cancer chemistry 030220 oncology & carcinogenesis Internal medicine biology.protein Endocrine system Medicine Cyclin-dependent kinase 6 business Abemaciclib |
Zdroj: | Annals of Oncology. 27:vi556 |
ISSN: | 0923-7534 |
Databáze: | OpenAIRE |
Externí odkaz: |